Ufuk Ilgen MD
Ufuk is a rheumatologist. Currently, he is doing his MSc in Translational Medical Research Programme at Heidelberg University, Germany. His main clinical and research interests are the immunopathological background of autoimmune diseases, the concept of autoimmunity and autoantibodies. He is a member of the Turkish Society for Rheumatology and the European Lupus Society. He is a member of the EMEUNET Country Liaisons Sub-Committe.
| Oral 0871 | Saturday, 16.11.24 15:00 Abstract Session: RA – Diagnosis, Manifestations, & Outcomes II: Bad Blood (Serologic and Imaging Biomarkers) Presenting author: J Rech (Germany) Title: Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”  This interesting study assessed the central nervous system representation of joint compression with functional MRI and revealed that a higher representation correlated with clinical response to treatment with a TNF inhibitor. |
| Poster 1349 | Sunday, 17.11.24 10:30 Poster Session B: RA – Diagnosis, Manifestations, & Outcomes Poster II Presenting author: J Sim (UK) Title: Two Composite Cytokine Scores Predict Flare and Drug-free Remission in Patients with Rheumatoid Arthritis This study reported serum cytokine scores with ability to predict flare and drug-free remission in RA patients after discontinuation of csDMARDs. In particular, the negative predictive value for flare was 77% in ACPA-negative patients. |
| Oral 1745 | Sunday, 17.11.24 15:00 Abstract Session: RA – Diagnosis, Manifestations, & Outcomes III: Best Day (RA Subpopulations) Presenting author: J Giles (USA) Title: Use of Statins and Its Association with Major Adverse Cardiovascular Outcomes with Tofacitinib versus TNF Inhibitors in a Risk-Enriched Population of Patients with Rheumatoid Arthritis Higher cardiovascular events were previously reported with tofacitinib compared to TNF inhibitors. In this post-hoc analysis of the post-authorisation safety study of tofacitinib, it was reported that only few patients with high cardiovascular risk took statins. Increased cardiovascular event rate with tofacitinib was only evident in patients with no statin use. |
| Poster 2244 | Monday, 18.11.24 10:30 Poster Session C: RA – Diagnosis, Manifestations, & Outcomes Poster III Presenting author: C Lopez-Pedrera (Spain) Title: Unveiling Synovial Protein Contributions to Serum Inflammation, Disease Activity, and Treatment Outcomes in RA Patients A ten-protein signature of the inflamed synovium and sera in RA was found to correlate one with the other. The signature was also associated with clinical features and treatment response. |
| Poster 2228 | Monday, 18.11.24 10:30 Poster Session C: RA – Diagnosis, Manifestations, & Outcomes Poster III Presenting author: C van Mullem (Belgium) Title: Feasibility, Safety, and Application for Clinical Indication and Research Purposes of Synovial Tissue Analysis in Rheumatoid Arthritis Mini-arthroscopy and ultrasound-guided synovial biopsies were reported to be safe, tolerable, and feasible, with good tissue yields for both clinical and research purposes. |